X-Biotix Therapeutics Names DeJonge as Executive
30 May 2019 - - David N. Cook Ph.D. has been elected to its board of directors of US-based biotechnology company X-Biotix Therapeutics, Inc. (X-Biotix), the company said.

Cook is an accomplished executive in the industry with extensive experience in the areas of the microbiome and bacterial targeting.

In addition, the company appointed Boudewijn DeJonge Ph.D., as senior director of biology.

DeJonge is a distinguished scientist and team leader with extensive discovery and development experience in the area of infectious diseases.

Cook has over 30 years of experience in the biopharma industry with experience in therapeutics, vaccines, small molecules, and biologics.

Specifically, he has worked on programs covering indications spanning infectious disease, vaccines, inflammation and immunology, and immuno-oncology. He was most recently the chief scientific officer at Seres Therapeutics, where he was responsible for defining research strategy and advancing key pipeline programs targeting the microbiome.

Prior to his role at Seres, Dr. Cook was EVP and COO at the International AIDS Vaccine Initiative, where he led the senior management team and oversaw the organization's strategy for ensuring the development of an AIDS vaccine for global use.

Over the span of his career, he has been involved in all aspects of product development including discovery research, clinical trials, regulatory affairs, manufacturing, business development, intellectual property and corporate operations, and has been directly responsible for obtaining the EU marketing authorization for four novel medical products.

With over 20 years of experience in the biopharmaceutical sector, DeJonge brings to the X-Biotix team his expertise in anti-bacterial drug discovery and development with specialty in areas of microbial physiology, bacterial resistance, cell envelope, and mode of action of compounds.

He was previously director of Microbiology at Pfizer, where he was responsible for providing clinical microbiology support in the development of antibiotic products during late-stage clinical development. Boudewijn has participated in and led multi-disciplinary teams at all phases of anti-bacterial drug discovery and development, from target identification to NDA filing.

Prior to his role at Pfizer, Boudewijn was an Associate director at AstraZeneca, where he led the microbiology efforts to support programs in discovery and development and was involved in the evaluation of external opportunities for in-licensing in the antibacterial area, spanning projects from early discovery to Phase 2 clinical development.

Gram-negative multi-drug-resistant infections represent a critical unmet medical need, with over 2m drug resistant infections in the US each year.

A report recently released by the World Health Organization predicts that by 2050, antibiotic resistance could cause 10 m deaths each year, surpassing the projected number of deaths due to cancer.

The landscape for commercialization of novel antibacterial therapies is rapidly evolving, and there remains a large market opportunity for both broad and narrow spectrum agents that target novel pathways without cross-resistance to existing antibiotics.

There is a particularly acute need for agents that address multi-drug resistant Gram-negative pathogens implicated in sepsis, hospital and ventilator acquired pneumonia (HAP and VAP), and other complicated hospital-acquired and community-based infections.

X-Biotix is a discovery and development company, with a focus on delivering the next generation of antibiotics to combat multi-drug resistant Gram-negative pathogens.

The company, incorporated in 2016 and located in Waltham, MA., is advancing multiple first-in-class small molecule compounds, identified using a unique DNA-encoded library platform, against a range of bacterial targets in essential pathways, which are predicted to defeat known antibiotics resistance mechanisms.